Form 4: Genelux Corp CFO Matthew Pulisic Awarded Stock Options

Genelux Corp's Chief Financial Officer, Matthew Pulisic, was granted 275,000 stock options with a strike price of $3.95, vesting over a period of 3.5 years.

Summary

• Matthew Pulisic, the Chief Financial Officer of Genelux Corp, was granted 275,000 stock options on January 31, 2025.
• The options have an exercise price of $3.95 per share.
• The options vest over time, with 25% vesting on January 30, 2026, and the remaining 75% vesting in 36 equal monthly installments thereafter.
• The options expire on January 30, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 25% after one year and the remainder over three years is a typical vesting structure.
• The exercise price of $3.95 is specific to the company's stock price at the time of the grant.

Stakeholder Impact

• Shareholders may view this positively as it incentivizes the CFO to work towards increasing the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, vesting, Genelux Corp, GNLX, Matthew Pulisic, CFO